BR0209604A - Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina - Google Patents

Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina

Info

Publication number
BR0209604A
BR0209604A BR0209604-8A BR0209604A BR0209604A BR 0209604 A BR0209604 A BR 0209604A BR 0209604 A BR0209604 A BR 0209604A BR 0209604 A BR0209604 A BR 0209604A
Authority
BR
Brazil
Prior art keywords
lower alkyl
neuricinin
undecan
diaza
oxa
Prior art date
Application number
BR0209604-8A
Other languages
English (en)
Inventor
Hai-Ying Cai
Michael Patrick Dillon
Guido Galley
Annick Goergler
Sabine Kolczewski
Dawn Marie Muszynski-Barsy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0209604A publication Critical patent/BR0209604A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE 1-OXA-3,9-DIAZA-SPIRO-5,5-UNDECAN-2-ONAS E SEU USO COMO ANTAGONISTA DO RECEPTOR PARA NEURICININA". A invenção refere-se a compostos de fórmula geral I em que (R^ 1^), independentemente um do outro é halogênio, alquila inferior ou alcóxi inferior; R^ 2^ é hidrogênio, alquila inferior, halogeno-alquila inferior, -(CH~ 2~)~ m~OH, -(CH~ 2~)~ m~-RN~ 2~, -(CH~ 2~)~ m~O-alquila inferior, -(CH~ 2~)~ m~-C(O)-NR~ 2~ ou é -(CH~ 2~)~ m~heteroarila de 6 membros, opcionalmente substituída com um ou mais alcóxi inferior, -(CH~ 2~)m-heterociclila não aromática de 5 ou 6 membros, opcionalmente substituída com hidróxi ou alquila inferior; R é hidrogênio ou alquila inferior e podem ser iguais ou diferentes no caso de R~ 2~; n é 0, 1 ou 2; m é 0, 1, 2, 3 ou 4; e sais de adição de ácido farmaceuticamente aceitáveis dos mesmos. Estes compostos possuem boa afinidade para o receptor de NK-1 e são portanto adequados para o tratamento de doenças relacionadas com este receptor.
BR0209604-8A 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina BR0209604A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
PCT/EP2002/004935 WO2002092604A1 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Publications (1)

Publication Number Publication Date
BR0209604A true BR0209604A (pt) 2004-03-23

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209604-8A BR0209604A (pt) 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina

Country Status (17)

Country Link
US (1) US6599900B2 (pt)
EP (1) EP1390372B1 (pt)
JP (1) JP4056887B2 (pt)
KR (1) KR100618063B1 (pt)
CN (1) CN1264847C (pt)
AR (1) AR033631A1 (pt)
AT (1) ATE401333T1 (pt)
AU (1) AU2002342238B2 (pt)
BR (1) BR0209604A (pt)
CA (1) CA2447329C (pt)
DE (1) DE60227657D1 (pt)
DK (1) DK1390372T3 (pt)
ES (1) ES2310206T3 (pt)
MX (1) MXPA03010321A (pt)
PT (1) PT1390372E (pt)
WO (1) WO2002092604A1 (pt)
ZA (1) ZA200308535B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554671A1 (en) 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
BRPI0608074A2 (pt) * 2005-03-03 2009-11-03 Janssen Pharmaceutica Nv derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
WO2008119663A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ES2823049T3 (es) 2015-07-31 2021-05-05 Pfizer Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
SG11201906417RA (en) 2017-01-20 2019-08-27 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201906427QA (en) 2017-01-23 2019-08-27 Pfizer Heterocyclic spiro compounds as magl inhibitors
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
JPH11512723A (ja) * 1995-09-29 1999-11-02 イーライ リリー アンド カンパニー フィブリノゲン依存血小板凝集抑制物質としてのスピロ化合物

Also Published As

Publication number Publication date
CN1264847C (zh) 2006-07-19
US6599900B2 (en) 2003-07-29
AU2002342238B2 (en) 2007-01-25
CA2447329C (en) 2009-07-28
ATE401333T1 (de) 2008-08-15
DE60227657D1 (de) 2008-08-28
AR033631A1 (es) 2003-12-26
JP4056887B2 (ja) 2008-03-05
CN1507449A (zh) 2004-06-23
PT1390372E (pt) 2008-08-25
ES2310206T3 (es) 2009-01-01
CA2447329A1 (en) 2002-11-21
JP2004534758A (ja) 2004-11-18
KR20030094405A (ko) 2003-12-11
ZA200308535B (en) 2005-01-31
US20030004163A1 (en) 2003-01-02
WO2002092604A1 (en) 2002-11-21
DK1390372T3 (da) 2008-09-15
MXPA03010321A (es) 2004-02-17
EP1390372B1 (en) 2008-07-16
EP1390372A1 (en) 2004-02-25
KR100618063B1 (ko) 2006-08-30

Similar Documents

Publication Publication Date Title
BR0014060A (pt) Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
BR0209604A (pt) Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
UY28149A1 (es) Compuestos quimicos
BR0000908A (pt) Derivados do 4-fenil-piridina
BR0111667A (pt) Novos compostos
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
BRPI0414447A (pt) derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
MXPA03001136A (es) Compuesto de 2-aminopiridina y uso medico del mismo.
BR0214666A (pt) Derivados de acetileno tendo atividade antagonìstica de mglur5
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
BR9808422A (pt) Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto
BRPI0412695A (pt) derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
NO933482L (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
BR0011863A (pt) Conjugados de fitosterol ou fitostanol com ácido ascórbico e uso destes no tratamento ou prevenção de doença cardiovascular
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
BRPI0606905A2 (pt) derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica contendo-os

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INTE.CL: C07D 498/10, A61K 31/535

Ipc: C07D 498/10 (2011.01), A61K 31/535 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.